Related Experiment Video
Updated: Aug 18, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Drug resistance and antiretroviral drug development
Robert W Shafer1, Jonathan M Schapiro
1Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA. rshafer@stanford.edu
Abstract:
As more drugs for treating HIV have become available, drug resistance profiles within antiretroviral drug classes have become increasingly important for researchers developing new drugs and for clinicians integrating new drugs into their clinical practice. In vitro passage experiments and comprehensive phenotypic susceptibility testing are used for the pre-clinical evaluation of drug resistance. Clinical studies are required, however, to delineate the full spectrum of mutations responsible for resistance to a new drug and to identify the settings in which a new drug is likely to be most useful for salvage therapy.
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Treatment Resistant Cancers
Viral Mutations
Inhibitors of Virion Maturation and Assembly
Pharmacokinetics in Pediatric Patients: Drug Excretion

